- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03593278
A Study to Evaluate ACT-246475 Fate in Healthy Male Subjects
November 15, 2022 updated by: Idorsia Pharmaceuticals Ltd.
Single-center, Open-label Study With 14C-radiolabeled ACT-246475 to Investigate Its Mass Balance, Pharmacokinetics, and Metabolism Following Single Subcutaneous Administration to Healthy Male Subjects
The purpose of this study is to investigate how quickly and to what extent ACT-246475 is absorbed, distributed, metabolized (broken down) and eliminated from the body.
ACT-246475 will be labeled with 14-Carbon (14C) and, in this way can be traced in blood, urine, and feces.
This study will also investigate how safe is ACT-246475 and how well it is tolerated when administered to healthy male volunteers.
Study Overview
Study Type
Interventional
Enrollment (Actual)
6
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Bad Krozingen, Germany, 79189
- Universitäts-Herzzentrum Bad Krozingen
-
Freiburg, Germany, 79106
- Universitats-Herzzentrum Freiburg
-
Ludwigshafen, Germany, 67063
- Klinikum der Stadt Ludwigshafen am Rhein gGmbH
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
45 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
Male
Description
Main Inclusion Criteria:
- Signed informed consent in the local language prior to any studymandated procedure,
- Healthy male subjects aged between 45 and 65 years (inclusive) at screening,
- No clinically significant findings on the physical examination at screening,
- Body mass index of 18.0-28.0 kg/m2 (inclusive) at screening,
- Systolic blood pressure (BP) 100-140 mmHg, diastolic BP 50-90 mmHg, and pulse rate 45-90 bpm (inclusive), measured on either arm, after 5 min in the supine position at screening,
- 12-lead electrocardiogram (ECG) without clinically relevant abnormalities, measured after 5 min in the supine position at screening,
- Values of closure time tested with the Platelet Function Analyzer equipment, for both cartridges of collagen/epinephrine and collagen/adenosine diphosphate below the upper limit of normal range at screening.
Main Exclusion Criteria:
- Known hypersensitivity to ACT-246475 or drugs of the same class, or any excipients of the ACT-246475 formulation,
- History or clinical evidence of any disease and/or existence of any surgical or medical condition, which might interfere with the absorption, distribution, metabolism or excretion of the study treatment (appendectomy and herniotomy allowed, cholecystectomy not allowed),
- Family or personal history of prolonged bleeding (e.g., after surgical intervention) or bleeding disorders (e.g., thrombocytopenia, clotting disturbances), intracranial vascular diseases, stroke, reasonable suspicion of vascular malformations, or peptic ulcers,
- Platelet count < 120 x10^9 L-1 at screening,
- Previous exposure to ACT-246475,
- Participation in another study with a radiation burden of > 0.1 mSv and ≤ 1.0 mSv in a period of 1 year prior to screening; a radiation burden of > 1 mSv and ≤ 2.0 mSv in a period of 2 years prior to screening, etc. (add 1 year per 1 mSv),
- Exposure to radiation for diagnostic reasons (except dental X-rays and plain X-rays of thorax and bony skeleton [excluding spinal column]), during work or during participation in a clinical study, in the period of 1 year prior to screening,
- Any circumstances or conditions, which, in the opinion of the investigator, may affect full participation in the study or compliance with the protocol.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment and observation period
On Day 1, the subjects will receive a single s.c.
dose of 16 mg 14C-radiolabeled ACT-246475 in the fasted state.
Subjects will be followed by an observation period of 3 days (72 h) during which blood, urine, and feces samples will be collected.
|
Single s.c.
dose of 16 mg ACT-246475 including 3.7 MBq (100 μCi) 14C-radiolabeled ACT 246475
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cumulative excretion of total 14C-radioactivity in urine and feces
Time Frame: Up to 54 days
|
Cumulative amount of total 14C-radioactivity excreted in urine and feces will be calculated by summing up the amount of total 14C-radioactivity of the samples excreted in each collection interval
|
Up to 54 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 27, 2018
Primary Completion (Actual)
August 5, 2018
Study Completion (Actual)
August 5, 2018
Study Registration Dates
First Submitted
July 10, 2018
First Submitted That Met QC Criteria
July 10, 2018
First Posted (Actual)
July 20, 2018
Study Record Updates
Last Update Posted (Actual)
November 16, 2022
Last Update Submitted That Met QC Criteria
November 15, 2022
Last Verified
November 1, 2022
More Information
Terms related to this study
Other Study ID Numbers
- ID-076-104
- 2017-004622-15 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Subjects
-
BiogenCompletedHealthy Adult Subjects | Healthy Elderly SubjectsUnited States
-
PfizerCompletedHealthy Adult Subjects and Healthy Elderly SubjectsBelgium
-
Lund UniversityCompletedHealthy Subjects | Diet, HealthySweden
-
PfizerRecruitingHealthy Subjects | Healthy ParticipantsUnited States
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedHealthy | Healthy Subjects | ImmunosuppressionUnited States
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
NeuShen TherapeuticsNot yet recruiting
-
GEN İlaç ve Sağlık Ürünleri A.Ş.Sulfateq B.V.Recruiting
-
Bio-innova Co., LtdNot yet recruiting
-
Bio-innova Co., LtdNot yet recruiting
Clinical Trials on ACT-246475
-
Idorsia Pharmaceuticals Ltd.CompletedHealthy SubjectsUnited States
-
Idorsia Pharmaceuticals Ltd.CompletedStable Coronary Artery DiseaseDenmark, Netherlands, Singapore, Canada, United Kingdom, United States, Germany, Sweden
-
Idorsia Pharmaceuticals Ltd.CompletedHealthy Subjects | Hepatic ImpairmentGermany
-
Idorsia Pharmaceuticals Ltd.CompletedAcute Myocardial InfarctionSwitzerland, Israel, Belgium
-
Idorsia Pharmaceuticals Ltd.Enrolling by invitationAcute Myocardial InfarctionUnited States, Spain, Denmark, Canada, Norway, France, China, United Kingdom, Hungary, Switzerland, Germany, Netherlands, Israel, Finland, Belgium, Czechia, Lithuania, Serbia, Austria, Italy, Bulgaria, Estonia, Poland, Romania, Slovakia, ...
-
Idorsia Pharmaceuticals Ltd.CompletedSafety, Tolerability, Pharmacokinetics and PharmacodynamicsFrance
-
Idorsia Pharmaceuticals Ltd.CompletedHealthy SubjectsNetherlands
-
Idorsia Pharmaceuticals Ltd.Completed
-
Idorsia Pharmaceuticals Ltd.Completed